Case report: Combination treatment proves effective for choroidal metastasis from breast cancer patient

Article

According to the authors, a patient with bilateral choroid metastases from breast cancer experienced "a dramatic response" after a combination treatment of abemaciclib and fulvestrant.

The combination treatment of abemaciclib and fulvestrant (estrogen receptor antagonist) provided a “dramatic response” in a patient with bilateral choroid metastases from breast cancer,1 according to senior author Carol Shields, MD, from the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia.

She and colleagues previously assessed 1,111 consecutive patients with uveal metastasis and found that breast cancer represented 37% of cases.2 In that same patient cohort, Welch et al.3 reported a mean interval of 6.5 years between the diagnosis of primary breast cancer and development of uveal metastasis.

Case report

A woman in her sixth decade of life was diagnosed with hormone receptor–positive and ERBB negative (HR+/ERBB−) invasive ductal breast carcinoma that metastasized to the lungs, brain, and spine. The patient also reported visual loss that examination showed was the result of a retinal detachment with choroidal metastases bilaterally.

The best-corrected visual acuities (BCVAs) were light perception and 20/50 in the right and left eyes, respectively. A total exudative retinal detachment with 1 large diffuse choroidal metastasis was seen in the posterior pole of the right eye and multifocal choroidal metastases (largest, 11 mm in basal diameter) in the left eye.

Ultrasonography confirmed a total serous retinal detachment and diffuse 2.5-mm choroidal thickening in the right eye and multifocal choroidal thickening in the left eye. Bilateral choroidal metastases were diagnosed, and the metastatic breast cancer was treated with systemic oral abemaciclib 150 mg twice daily, and fulvestrant 500 mg intramuscular injection monthly. The abemaciclib dose was later reduced to 100 mg orally twice daily because of nausea, diarrhea, and anorexia.

Four months after the start of treatment, the metastases regressed with almost complete resolution of the retinal detachment in the right eye; the BCVAs improved to 20/50 and 20/20 in the right and left eyes, respectively, Shields reported.

A previous study4 reported that abemaciclib is a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 that is a treatment option for HR+/ERBB2− breast cancer. The authors reported that abemaciclib plus fulvestrant significantly extended the progression-free survival compared with fulvestrant alone (median, 16.4 vs. 9.3 months; hazard ratio, 0.553; 95% confidence interval, 0.449-0.681; p < 0.001).

Regarding the current case, Shields commented, “We cannot be certain of the results in similar presentations or what effects will be noted beyond 4 months. In this report, we observed substantial regression of bilateral choroidal breast cancer metastases in a single case followed through 4 months with resolution of a total exudative retinal detachment in 1 eye without ocular radiotherapy.”

References
  1. Barke MR, Agraal KU, Shields CL. Abemaciclib and fulvestrant for bilateral choroidal metastasis from breast carcinoma. JAMA Ophthalmol. Published online September 8, 2022. doi:10.1001/jamaophthalmol.2022.3453
  2. Shields CL, Welch RJ, Malik K, et al. Uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin. Middle East Afr J Ophthalmol. 2018;25(2):81-90. doi:10.4103/meajo.MEAJO_6_18
  3. Welch RJ, Malik K, Mayro EL, et al. Uveal metastasis in 1111 patients: interval to metastasis and overall survival based on timing of primary cancer diagnosis. Saudi J Ophthalmol. 2019;33(3):229-237. doi:10.1016/j.sjopt.2019.07.006
  4. Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women With HR+/HER2—advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.